Skip to content

MDMA: all studies

Page 123 of 346: studies 1,221 to 1,230 of 3,454, newest first. Back to the MDMA overview

Research

Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review.

CJEM September 2010 Brian E Grunau, Matthew O Wiens, Jeffrey R Brubacher

The use of dantrolene in the treatment of hyperpyrexia related to MDMA (3,4-methylenedioxymethamphetamine) is controversial, with little data available to guide clinical decision-making. Although the treatment is recommended by several poison control centres, published data are primarily in the form of case reports and animal and in vitro experiments. We conducted a systematic review to...

Dantrolene for the treatment of MDMA toxicity.

CJEM September 2010 Brian E Grunau, Matthew O Wiens, Marc Greidanus

MDMA (3,4-methylenedioxymethamphetamine), popularly known as “Ecstasy,” was first introduced and patented by Merck & Co., Inc., in 1914 as an appetite suppressant. Currently, its primary role is as an illegal stimulant used to produce a euphoric effect during parties. This case report de scribes a 31-year-old man who, after taking 3 tablets of Ecstasy, presented to an emergency department with...

Preliminary evidence of motor impairment among polysubstance 3,4-methylenedioxymethamphetamine users with intact neuropsychological functioning.

Journal of the International Neuropsychological Society August 25, 2010 Chad A Bousman, Mariana Cherner, Kristen T Emory et al.

Neuropsychological disturbances have been reported in association with use of the recreational drug "ecstasy," or 3,4-methylenedioxymethamphetamine (MDMA), but findings have been inconsistent. We performed comprehensive neuropsychological testing examining seven ability domains in 21 MDMA users (MDMA+) and 21 matched control participants (MDMA-). Among MDMA+ participants, median [interquartile...

DOI: 10.1017/s1355617710000846 (opens in new tab) Full text (opens in new tab) Humans Movement disorders Amphetamine-related disorders Substance withdrawal syndrome +5

Evidence of increased activation underlying cognitive control in ecstasy and cannabis users.

Neuroimage August 15, 2010 Gloria M P Roberts, Hugh P Garavan

Evidence suggests that users of ecstasy (3,4-methylenedioxymethamphetamine) have behavioural and cognitive deficits and show increased impulsivity. Impulse control impairments have been shown to be common to a number of addictive behaviours and may constitute a risk factor for drug abuse and dependence. The aim of this study was to investigate brain activation during response inhibition and...

Myocardial expression of TNF-alpha, IL-1beta, IL-6, IL-8, IL-10 and MCP-1 after a single MDMA dose administered in a rat model.

Current Pharmaceutical Biotechnology August 2010 Margherita Neri, Stefania Bello, Alessandro Bonsignore et al.

Indirect effects of 3,4-methylenedioxy-N-methylamphetamine (MDMA) and metabolites on the cardiac cells are well-known, the mechanism(s) underlying direct MDMA-induced cardiotoxicity remaining to be clarified. To better understand the immuno-inflammatory phenomena accompanying the cardiac alterations during MDMA administration, we conducted a study in an in vivo animal model to evaluate the...

Mechanisms underlying the hepatotoxic effects of ecstasy.

Current Pharmaceutical Biotechnology August 1, 2010 Márcia Carvalho, Helena Pontes, Fernando Remião et al.

3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) is a worldwide illegally used amphetamine-derived designer drug known to be hepatotoxic to humans. Jaundice, hepatomegaly, centrilobular necrosis, hepatitis and fibrosis represent some of the adverse effects caused by MDMA in the liver. Although there is irrefutable evidence of MDMA-induced hepatocellular damage, the mechanisms responsible for...

DOI: 10.2174/138920110791591535 (opens in new tab) Full text (opens in new tab) Liver Animals Humans N-methyl-3,4-methylenedioxyamphetamine +2